Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer

Michelle Camarata(Yale University), Sarah P. Blagden(Churchill Hospital), Sue Copley(Imperial College Healthcare NHS Trust), Roger P. Davies(Imperial College Healthcare NHS Trust)

BMJ Case Reports

April 23, 2013

10.1136/bcr-2013-009532

Cited by 13

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

|eLife|2017|201

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

|Clinical Cancer Research|2011|168